|
**Overview**: FISH t(11;14) IGH CCND1 Panel**Introduction**: The FISH t(11;14) IGH CCND1 Panel is a diagnostic tool designed to detect t(11;14) in lymphoma using whole blood or bone marrow samples. In India, mantle cell lymphoma (MCL) accounts for ~5-10 percent of non-Hodgkin lymphomas (~4,000-6,000 cases/year), with t(11;14)(q13;q32) IGH/CCND1 translocation present in nearly all cases, leading to cyclin D1 overexpression and aggressive behavior. High morbidity from under-testing in rural/low-SES lymphoma patients, limited FISH labs, delayed intensive therapy (R-CHOP + bortezomib or BTKi) leading to early relapse or mortality. Per hematology practices aligned with ICMR and Indian Society of Hematology guidelines, the test employs fluorescence in situ hybridization (FISH) for IGH/CCND1 translocation over 1-2 days with high sensitivity/specificity, valuable for rapid MCL confirmation and differential diagnosis from other B-cell lymphomas. This diagnostic falls under genetic cancer screening and targets patients with suspected MCL (lymphadenopathy, GI involvement, high LDH), addressing accurate detection to guide targeted therapy and prognosis. With elevated morbidity due to under-testing, the test supports public health efforts by enabling precise molecular diagnosis and improving survival. Its blood/bone marrow-based approach ensures reliable translocation detection in India's expanding lymphoma centers.**Other Names**: FISH t(11;14) Pnl.**FDA Status**: FDA approved, CLIA certified for cytogenetics/oncology, compliant with 2025 standards.**Historical Milestone**: t(11;14) FISH diagnostic for MCL; in India, used in lymphoma protocols.**Purpose**: The test detects 2 parameters including IGH/CCND1 translocation to guide lymphoma genetic assessment, confirm MCL, inform therapy/prognosis.**Test Parameters**: 1. IGH/CCND1 Translocation, 2. Chromosomal Rearrangement.**Pretest Condition**: No fasting required; patients should have suspected mantle cell lymphoma.**Specimen**: 3 mL whole blood or bone marrow in 1 EDTA tube, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 48 hours with proper handling to preserve cell viability, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: Not applicable (fresh sample preferred for FISH).**Medical History**: Patients should provide details on lymphadenopathy, GI symptoms, prior therapy.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of undetected t(11;14) including aggressive progression, benefits of detection, and minimal discomfort from blood/bone marrow draw.**Procedural Considerations**: The test involves sample processing using FISH by trained personnel to ensure sterile technique, avoid contamination, and interpret results within 1-2 days using provided probes/controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, or low tumor burden can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Positive IGH/CCND1 translocation confirms MCL, necessitating specialist input. Negative may require follow-up if suspicion high.**Specialist Consultation**: Hematologists/oncologists should be consulted for management.**Additional Supporting Tests**: Cyclin D1 IHC, karyotype for confirmation.**Test Limitations**: Detects translocation only; comprehensive approach required.**References**: Indian Journal of Hematology 2024, Lymphoma Studies India 2023. |
